Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2002-04-18
2003-09-16
Fonda, Kathleen K. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S054000, C514S062000, C514S169000, C514S171000
Reexamination Certificate
active
06620793
ABSTRACT:
BACKGROUND AND FIELD OF THE INVENTION
Spinal cord injury is a devastating injury with, today, no significantly useful therapy. Emergency medical treatment for spinal-cord injury patients has included prompt triage and intensive rehabilitation. These therapies have somewhat increased or optimized remaining neurologic functions in those patients and prevented further injury to the spinal cord. However, only a minority of patients ever achieve any major neurologic recovery. As a result, no effective acute treatment or rehabilitation therapy is presently available for the approximately 10,000 patients per year which suffer from major spinal cord injury and the consequent permanent disability.
Development of effective treatments is also made more difficult because it is difficult to extrapolate to therapy in humans from animal studies. There is significant controversy about whether any and which animal models best simulate spinal cord injuries in humans, about whether the models are reproducible, and therefore whether studies in animals provide useful information for possible human therapy. It is, therefore, one object of the present invention to provide a method for neurological recovery in humans with spinal cord injury by administration of the ganglioside GM
1
.
It is another object of the present invention to provide a combination therapy for the treatment of spinal cord injury comprised of administration of the ganglioside GM
1
and preferably methylprednisolone.
REFERENCES:
patent: 4849413 (1989-07-01), della Valle et al.
patent: 4851521 (1989-07-01), della Valle et al.
patent: 4940694 (1990-07-01), della Valle et al.
patent: 5068224 (1991-11-01), Fryklund et al.
Geisler, F.H. et al., New England Journal of Medicine, 324, No. 26, pp. 1829-1838 (Jun. 1991).
Walker, M.D., New England Journal of Medicine, 324, No. 26, pp. 1885-1887 (1991).
Sabel, B.A., Pharmacological Approaches to the Treatment of Brain and Spinal Cord Injury, ed. D.G. Stein and B.A. Sabel, Chapter 9, pp. 167-194 (1988).
Janssen et al., SPINE, vol. 14, No. 1, pp. 23-32 (1989).
Hadjiconstantinou, M. et al., Brain Research, vol. 366, pp. 343-345 (1986).
Geisler, F.H. et al., Acta Neurobiol. Exp., vol. 50, pp. 515-521 (1990).
Young, W., Neural Regeneration and Transplantation, pp. 157-169 (1989).
Beattie, M.S. et al., Pharmacological Approaches to the Treatment of Brain and Spinal Cord Injury, ed. D.G. Stein and B.A. Sabel, Chapter 3, pp. 43-73 (1988).
Leon, A. et al., Supplement III, Stroke, vol. 21, No. 11, pp. 95-97 (1990).
Carolei, A. et al., Cerebrovascular and Brain Metabolism Reviews, vol. 3, pp. 134-157 (1991).
Geisler, F.H. et al., Ricerche Sperimentali, pp. 167-172, in “I tumori primitivi del midollo spinale”. C.A. Pagani et al, eds., Torino, Minerva Medica 1991.
Geisler et al., abstracts from the AANS and CNS, and the Symposium of the XXXI Int. Congress of Physiol. Sci., Cancun, Mexico—Feb. 12, 1989; Warsaw, Poland—Jul. 4-7, 1989; Rome, Italy—Feb. 20-23, 1991.
Hall et al., Chemical Abstracts 101:84196h (1984); 105:91569t (1986).
Braughler et al., Chemical Abstracts 101:123343a (1984).
Bose et al., Chemical Abstracts 104:102429e (1986).
Fusco et al., Chemical Abstracts 105:131574z (1986).
Braughler et al., Chemical Abstracts 107:90251n (1987).
Gorio et al., Chemical Abstracts 107:147151m (1987).
Fusco et al., Chemical Abstracts 110:1528e (1989).
Holtz et al., Chemical Abstracts 115:22443s (1991).
Young, W., Neurology Neurosurgery & Psychiatry, vol. 55, pp. 635-639 (1992).
Fishman et al., Science, 194, pp. 906-915 (1976).
Willinger et al., Dev. Biol., 74, pp. 101-117 (1980).
Obata et al., Integrative Control Functions of the Brain, Ed. Ito et al., 2, pp. 5-14 (1979).
Gorio et al., Brain Research, 197, pp. 236-241 (1980).
Syennerholm, J. Neurochem. 10, pp. 613-623 (1963).
Tettamanti et al., Biochimica et Biophysica Acta, 296, pp. 160-170 (1973).
Purpura et al., Brain Research, 143, pp. 13-26 (1977).
Commissiong et al., Brain Research, 380, pp. 205-215 (1986).
Sabel et al., Nature, 323, p. 493 (1986).
Braughler et al., J. Neurosurg. 61:290-295 (1984).
Bose et al., Neuroscience Letters 63:165-169 (1986).
Hall et al., Exp. Brain Res. (Suppl. 13):63-73 (1986).
Braughler et al., J. Neurosurg. 67:102-105 (1987).
Bracken et al., New Engl. J. Med., 322 (20):1405-1411 (May 17, 1990).
Hall, Neurosteroids & Brain Function, Fidia Res. Series, vol. 8, pp. 55-60, (1991).
Leon Alberta
Massarotti Marino
Toffano Gino
Birch & Stewart Kolasch & Birch, LLP
Fidia Farmaceutici S.p.A.
Fonda Kathleen K.
Svensson Leonard R.
LandOfFree
Therapeutic use of ganglioside GM1 in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic use of ganglioside GM1 in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of ganglioside GM1 in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3087086